Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Zhu Y, Jean-Baptiste M, Lenderking WR, Bell JA, Revicki DA, Lin HM, Brake R, Reeve BB. Zhu Y, et al. Among authors: brake r. Cancer Med. 2023 Mar;12(5):5494-5505. doi: 10.1002/cam4.5376. Epub 2022 Dec 30. Cancer Med. 2023. PMID: 36583557 Free PMC article.
Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.
Han H, Li S, Chen T, Fitzgerald M, Liu S, Peng C, Tang KH, Cao S, Chouitar J, Wu J, Peng D, Deng J, Gao Z, Baker TE, Li F, Zhang H, Pan Y, Ding H, Hu H, Pyon V, Thakurdin C, Papadopoulos E, Tang S, Gonzalvez F, Chen H, Rivera VM, Brake R, Vincent S, Wong KK. Han H, et al. Among authors: brake r. Cancer Res. 2021 Oct 15;81(20):5311-5324. doi: 10.1158/0008-5472.CAN-21-1526. Epub 2021 Aug 11. Cancer Res. 2021. PMID: 34380634 Free PMC article.
Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.
Zhang S, Jin S, Griffin C, Feng Z, Lin J, Baratta M, Brake R, Venkatakrishnan K, Gupta N. Zhang S, et al. Among authors: brake r. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1028-1043. doi: 10.1002/cpdd.951. Epub 2021 Jun 12. Clin Pharmacol Drug Dev. 2021. PMID: 34118178 Free PMC article. Clinical Trial.
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, Menéndez S, Soria-Jiménez L, Martínez A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J. Hernández-Prat A, et al. Among authors: brake r. Mol Cancer Res. 2019 Sep;17(9):1931-1944. doi: 10.1158/1541-7786.MCR-18-0923. Epub 2019 Jun 3. Mol Cancer Res. 2019. PMID: 31160383
The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL. Lewis RT, et al. Among authors: brake rl. J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10. J Med Chem. 2012. PMID: 22734674
22 results